Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

Mini oral session - Gastrointestinal tumours, non-colorectal

LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)

Date

17 Sep 2021

Session

Mini oral session - Gastrointestinal tumours, non-colorectal

Topics

Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Alexander Stein

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

A. Stein1, L. Paschold2, J. Tintelnot3, E. Goekkurt1, P.C. Thuss-Patience4, S. Lorenzen5, T.J. Ettrich6, J. Riera Knorrenschild7, L. Jacobasch8, A. Kretzschmar9, S. Kubicka10, S. Al-Batran11, A. Reinacher-Schick12, D. Pink13, M. Sinn3, U. Lindig14, A. Hinke15, S. Hegewisch Becker16, M. Binder2

Author affiliations

  • 1 University Cancer Center Hamburg, Hematology-Oncology Practice Eppendorf, 20249 - Hamburg/DE
  • 2 Department Of Internal Medicine Iv, Oncology/hematology, Martin-Luther-University Halle-Wittenberg, 06120 - Halle/DE
  • 3 Department Of Oncology, Hematology And Bmt With Division Of Pneumology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 4 Hematology Oncology Dept., Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 5 Hematology And Oncology, Rechts der Isar Hospital,TUM, 81675 - Munich/DE
  • 6 Department Of Internal Medicine I, University of Ulm, 89081 - Ulm/DE
  • 7 Oncology/hematology, Universitätsklinikum Marburg, 35043 - Marburg/DE
  • 8 Oncology/heamatology Department, Gemeinschaftspraxis Haematologie - Onkologie, 01307 - Dresden/DE
  • 9 Oncology Dept., Klinikum St. Georg gGmbH, 04129 - Leipzig/DE
  • 10 Cancer Center Reutlingen, Klinikum am Steinenberg Reutlingen, 72764 - Reutlingen/DE
  • 11 Institute Of Clinical Cancer Research, Nordwest-Krankenhaus, 60488 - Frankfurt am Main/DE
  • 12 Dept. Of Hematology, Oncology And Palliative Care, Katholisches Klinikum Bochum - St. Josef-Hospital, 44791 - Bochum/DE
  • 13 Klinik Und Poliklinik Für Innere Medizin C, University Greifswald, HELIOS Klinikum Bad Saarow, 15526 - Bad Saarow/DE
  • 14 Oncology/hematology, University Hospital Jena, Friedrich-Schiller-University, 7740 - Jena/DE
  • 15 Na, CCRC - Cancer Clinical Research Consulting, 40595 - Düsseldorf/DE
  • 16 Oncology And Hematology Department, Facharztzentrum Eppendorf, 20249 - Hamburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract LBA54

Background

In 1st line EGA, the addition of PD-1 inhibitors to chemotherapy improved outcome in selected patient populations. The INTEGA trial compared different immunotherapy regimens in 1st line HER2+ EGA.

Methods

INTEGA is a randomized exploratory phase II investigator initiated trial with two experimental arms. Patients (pts) with previously untreated (for advanced disease) HER2+ (local status - IHC3+ or 2+/ISH+) EGA were randomized to receive trastuzumab (trast) and nivolumab (nivo) (240mg or 1mg/kg with ipi) in combination with either ipilimumab (ipi) (4x 3mg/kg every 3 weeks) (arm A) or mFOLFOX6 (arm B) for up to 12 months. The 1° endpoint was to increase the 12month overall survival rate (OSR@12) from 55% (trast/chemo - ToGA regimen) to 70% in each arm.

Results

Between March 2018 and May 2020 a total of 97 pts were enrolled and 88 randomized (44 per arm) in 21 German sites. Baseline characteristics were female/male 18/70, median age 61 (range 41-80), ECOG 0/1 54/34, GEJ/stomach 66/22, prior surgery for primary tumor in 24 patients and were well balanced between groups. Central posthoc biomarker analysis (ongoing) yet showed PD-L1 CPS>1 in 55 and >5 in 41 pts and HER2 positivity in 76 pts while 8 were negative (incl. one failed ISH). The 1° endpoint of 70% OSR@12 was reached in arm B, but not in arm A (57%) (Table). Treatment related grade 3/4 AE/SAE occurred in 29/15 pts in arm B and in 20/17 pts in arm A. Liquid biopsy analyses showed strong correlation of high ctDNA load with shorter PFS/OS and emergence of truncating HER2 mutations on trast. Table: LBA54

All (n=88) CPS>1 (n=55) CPS>5 (n=41)
Arm A Arm B Arm A Arm B Arm A Arm B
ORR 32% 56% 38% 65% 29% 68%
mPFS 3.2 mo 10.7 mo 2.2 mo 11 mo 2 mo 11 mo
PFSR@12 15% 37% 15% 34% 7% 37%
mDOR 5.8 mo 9.2 mo - - - -
mOS 16.4 mo 21.8 mo 16.4 mo 21.8 mo 12.5 mo 22.4 mo
OSR@12 57% 70% 54% 70% 51% 69%

mPFS – median PFS, PFSR@12 - PFS rate at 12 months, mDOR - duration of response, OSR@12 - OS rate at 12 months, mo - months

Conclusions

Trast/nivo/FOLFOX showed increased efficacy compared to the ToGA regimen, whereas trast/nivo/ipi did not improve OS over trast/chemo. Subgroupanalyses are ongoing and will be presented.

Clinical trial identification

NCT03409848.

Editorial acknowledgement

Legal entity responsible for the study

AIO Studien gGmbH.

Funding

Bristol Myers-Squibb.

Disclosure

A. Stein: Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal and Institutional, Invited Speaker: BMS; Financial Interests, Personal and Institutional, Advisory Board: BMS. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.